Creative Enzymes, a global enzyme technology service provider based in New York, NY, has launched an AI-integrated biocatalysis platform designed to accelerate enzyme development for industrial applications. The platform merges computational enzyme engineering with hands-on process development to deliver AI-Driven Biocatalysis Solutions that are both predictable in silico and practical at industrial scale.
The announcement highlights a persistent gap between identifying biocatalysis opportunities and having suitable enzymes available. Traditional development methods cannot keep pace with iterative product development cycles. According to the company, AI addresses this by predicting enzyme candidates for specific reactions, designing enzymes constrained by process parameters rather than biological factors, and leveraging molecular features to anticipate process performance early. This reduces the need for extensive experimental testing, cutting R&D costs and lowering the risk of process failure.
The platform offers three service modules: AI-Driven Industrial Biocatalysis, AI-Driven Green Biocatalysis, and an end-to-end solution for biocatalyst discovery and engineering. The latter spans the entire value chain from target reaction analysis to scale-up characterization, including computational screening, process optimization across temperature, pH, solvent, substrate loading, and cofactor availability, and scale-up evaluation of expression yield and operational half-life. For moderately complex targets, the design-build-test-learn cycle is reduced from 12–24 months to 8–12 months.
AI-Driven Industrial Biocatalysis focuses on bridging lab-scale performance and commercial production, addressing substrate concentration optimization, cofactor regeneration, product inhibition management, immobilization, formulation development, and integration of process analytical technology. The goal is to deliver complete technology transfer packages, including SOPs and regulatory documentation. AI-Driven Green Biocatalysis targets sustainability, leveraging enzymatic reactions that occur in aqueous media at room temperature, reducing organic solvent use, heating/cooling requirements, byproduct formation, and waste generation.
A recent case study demonstrated the platform's capabilities in transaminase engineering. Researchers developed a 6D protein engineering framework combining interaction energy, solvent effects, and 1.39 million structural fragments to predict beneficial mutations. Five AI-selected transaminase variants, each with nine mutations, showed high solubility and catalytic stability at 7-liter fermentation scale. The engineered enzymes converted prochiral ketones to sitagliptin, achieving enantiomeric purity over 99% and conversion rates up to 89% during scale-up production.
The implications of this platform are significant across industries. In pharmaceuticals, AI biocatalysis is already enabling asymmetric synthesis of chiral intermediates and replacing hazardous reagents. Agrochemicals are using it to fine-tune toxicology profiles, while the food industry applies it for cleaner labels through enzymatic modification. Fine chemicals and personal care are exploring high-value conversions and more sustainable processes. By accelerating enzyme development and reducing costs, Creative Enzymes' platform could expand the adoption of biocatalysis, making manufacturing more efficient and environmentally friendly.
